← All trials
NCT05046262
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 8, 2020
- Primary completion
- Feb 22, 2022
- Completion date
- Feb 22, 2022
- First posted
- Sep 16, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 25
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenReponsible party - principal investigator
- Mirai Medical, IrelandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.